Marvin Chum

St Joseph's Healthcare Hamilton
Hamilton, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Erratum: Consequences of the Novel ALS-Associated KIF5A Variant c.2993-6C>A for Exon 27 Splicing and Axonal Transport of SFPQ.

Erratum: Consequences of the Novel ALS-Associated KIF5A Variant c.2993-6C>A for Exon 27 Splicing and Axonal Transport of SFPQ.

Journal: Neurology. Genetics

Published: July 24, 2026

A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada.

A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada.

Journal: European journal of human genetics : EJHG

Published: March 24, 2026

Differentiating upper- and lower motor neuron diseases using automated acoustic analysis.

Differentiating upper- and lower motor neuron diseases using automated acoustic analysis.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: June 01, 2025

Consequences of the Novel ALS-Associated KIF5A Variant c.2993-6C > A for Exon 27 Splicing and Axonal Transport of SFPQ.

Consequences of the Novel ALS-Associated KIF5A Variant c.2993-6C > A for Exon 27 Splicing and Axonal Transport of SFPQ.

Journal: Neurology. Genetics

Published: May 16, 2025

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Journal: Muscle & nerve

Published: May 02, 2025

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).

Journal: Muscle & nerve

Published: October 23, 2024

Assessing the Measurement Properties of the Self-Administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): A Rasch Analysis.

Assessing the Measurement Properties of the Self-Administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): A Rasch Analysis.

Journal: Physical therapy

Published: November 26, 2022

Refining items for a preference-based, amyotrophic lateral sclerosis specific, health-related quality of life scale.

Refining items for a preference-based, amyotrophic lateral sclerosis specific, health-related quality of life scale.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: February 11, 2022

Trainee Distress When Faced with End-of-Life Care in Neurology: A Qualitative Analysis.

Trainee Distress When Faced with End-of-Life Care in Neurology: A Qualitative Analysis.

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: January 03, 2022

Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices.

Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: September 27, 2021

The Value of Nerve Biopsy in Transthyretin Amyloidosis with Competing Comorbidities.

The Value of Nerve Biopsy in Transthyretin Amyloidosis with Competing Comorbidities.

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: July 19, 2021

Do Generic Preference-Based Measures Accurately Capture Areas of Health-Related Quality of Life Important to Individuals with Amyotrophic Lateral Sclerosis: A Content Validation Study.

Do Generic Preference-Based Measures Accurately Capture Areas of Health-Related Quality of Life Important to Individuals with Amyotrophic Lateral Sclerosis: A Content Validation Study.

Journal: Patient related outcome measures

Published: March 30, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026